Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to moxifloxacin: Moxifloxacin hydrochloride


An antibiotic drug of the fluoroquinolone class, C21H24FN3O4, used primarily to treat respiratory, sinus, and skin infections.

[m(eth)- + alteration of oxy- + -floxacin, fluoroquinolone suff.; see ciprofloxacin.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n moxifloxacino, moxifloxacina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The adopted antibiotic regimen included clarithromycin 61 mg/ kg, moxifloxacin 25 mg/kg, and ethambutol 60 mg/ kg administered by crop gavage every 12 hours for 18 weeks.
The updated warnings apply to all approved fluoroquinolones: levofloxacin (Levaquin), ciprofloxacin (Cipro), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), and gemifloxacin (Factive).
genitalium] exists." Persistent cases of nongonococcal urethritis, cervicitis, and possibly pelvic inflammatory disease could benefit from treatment with moxifloxacin (Avelox), Dr.
Moxifloxacin is a fourth generation synthetic fluoroquinolone antibacterial agent that is active against both Gram positive and Gram negative bacteria.
There is more news about moxifloxacin. Pardillo et al.
The patient was treated with moxifloxacin and ceftazidime for 4 weeks more but moxifloxacin had to be stopped because of Q-T interval prolongation and amikacin was initiated.
A large-scale, pivotal phase III clinical trial in TB patients is beginning with the antibiotic moxifloxacin, already approved for other respiratory indications.
In both the trials, the treatment with the company's Xenleta was compared to another antibiotic, moxifloxacin with or without linezolid.
The FDA approval was based on a clinical development program supported by a robust data package, including two pivotal, Phase 3 trials (known as LEAP 1 and LEAP 2) that evaluated the safety and efficacy of IV and oral XENLETA compared to moxifloxacin in the treatment of adults with CABP.
Approval was based on data from two clinical trials of 1,289 patients with community-acquired bacterial pneumonia comparing Xenleta taken orally or intravenously to treatment with moxifloxacin with or without linezolid.
Each subject will be randomly sequenced through all three study periods: oliceridine, placebo, and moxifloxacin as a positive control.